Lymphoma, B-Cell News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Clinical Collab to Evaluate Yescarta and Utomilumab in Large B-Cell Lymphoma - Drug Discovery & Development



Clinical Collab to Evaluate Yescarta and Utomilumab in Large B-Cell Lymphoma 
Drug Discovery & Development
Kite, a Gilead Co., announced it has entered into a clinical trial collaboration with Pfizer to evaluate the safety and efficacy of the investigational combination of Yescarta (axicabtagene ciloleucel) and Pfizer's utomilumab, a fully humanized 4-1BB ...
Kite, Pfizer to Assess Yescarta-Utomilumab Combination in Lymphoma Genetic Engineering & Biotechnology News

all 2 news articles » 


CAR T-Cell Therapy Gets Priority Review for Lymphoma Treatment - Curetoday.com



Curetoday.com
 
CAR T-Cell Therapy Gets Priority Review for Lymphoma Treatment 
Curetoday.com
CAR T-Cell Therapy Gets Priority Review for Lymphoma Treatment. The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for Kymriah (tisagenlecleucel) to be used to treat adult patients ...
Kymriah Granted Priority Review for Diffuse Large B-Cell Lymphoma Specialty Pharmacy Times
Novartis gets US priority review for Kymriah for adults with lymphoma Nasdaq
FDA Grants Priority Review to CAR T-Cell Therapy Tisagenlecleucel for DLBCL www.oncnursingnews.com/
Healio  -OncLive  -Reuters 
all 17 news articles » 


FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma - Lymphoma News Today



Lymphoma News Today
 
FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma 
Lymphoma News Today
The U.S. Food and Drug Administration (FDA) will prioritize the regulatory review of Novartis' application to use Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Novartis hopes ...

and more » 


Gilead/Kite team up with Pfizer for CAR-T-mAb combination ... - FierceBiotech



FierceBiotech
 
Gilead/Kite team up with Pfizer for CAR-T-mAb combination ... 
FierceBiotech
Gilead and its shiny new $12 billion biotech buy Kite Pharma have teamed up with Big Pharma Pfizer to work on a Yescarta-utomilumab combination test in certain blood cancers. Yescarta (axicabtagene ciloleucel), approved by the FDA last year in the ...
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a ... Endpoints News

all 3 news articles » 


Cutaneous B- Cell Lymphoma Drug Profiles and Clinical Trials ... - Business Wire (press release)



Cutaneous B- Cell Lymphoma Drug Profiles and Clinical Trials ... 
Business Wire (press release)
Lymphoma is a cancer type where uncontrollable growth of lymphocytes (WBCs) initiating from lymph glands or lymphatic tissue or other parts of the lymphatic system, including bone marrow, tonsils, testicles, spleen and lymph nodes. This excess growth ...

and more » 


Online crowdfunding effort started to help local family - Northwest Georgia News



Northwest Georgia News
 
Online crowdfunding effort started to help local family 
Northwest Georgia News
Making a lengthy commute to Atlanta each morning naturally becomes much more difficult when diagnosed with Lymphoma. ?They supply a truck and gas and what not,? Gene said. ?I've always worked hard and not being able to is a crippling blow,? Gene said ...

 


Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA - Nasdaq



Pharmaceutical Business Review
 
Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA 
Nasdaq
Novartis AG'sNVS supplemental Biologics License Application (sBLA) for Kymriah suspension for intravenous infusion, for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are ineligible for or ...
Novartis' Kymriah nabs speedy reviews in US, Europe for lymphoma treatment Pharmaceutical Business Review
Novartis' Kymriah receives accelerated review status in US and ... Zenopa
US FDA grants priority review status to Novartis' sBLA for Kymriah to ... pharmabiz.com

all 7 news articles » 


Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense - Investor's Business Daily



Investor's Business Daily
 
Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense 
Investor's Business Daily
Juno looks likely to gain approval later this year for its therapy, JCAR017, to treat diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma. Gilead already has a therapy approved there. Novartis is also seeking an approval for this ...
Juno stock jumps as reports suggest Celgene wants a buyout FierceBiotech
Celgene in talks to buy CAR-T partner Juno pharmaphorum
What's Juno Therapeutics Worth to Celgene? Madison.com
Motley Fool  -Frisco Fastball  -Bibeypost.com  -Wall Street Journal 
all 167 news articles » 


Juno Hits 52-Week High on Celgene's Rumored Buyout Interest - Nasdaq



CNBC
 
Juno Hits 52-Week High on Celgene's Rumored Buyout Interest 
Nasdaq
JCAR017 is presently undergoing a phase I pivotal TRANSCEND study for non-Hodgkin lymphoma (NHL) including those with diffuse large B cell lymphoma (DLBCL), follicular lymphoma grade 3B or mantle cell lymphoma (MCL). Juno reported promising additional ...
A major cancer drugmaker may need to buy its way out of a looming disaster CNBC

all 3 news articles » 


Predicting and Analyzing Response in Follicular Lymphoma - OncLive - OncLive



OncLive
 
Predicting and Analyzing Response in Follicular Lymphoma - OncLive 
OncLive
Ian W. Flinn, MD, PhD; Peter Martin, MD, MS; Grzegorz S. Nowakowski, MD; Anas Younes, MD; and Loretta J. Nastoupil, MD, provide their perspectives on the value of MRD status and POD24 to predict outcomes in follicular lymphoma.

and more »